Recombinant Oxalate decarboxylase

重组草酸脱羧酶

Report date: 2023/03/06 20:00:20

Base Information

Drug NameRecombinant Oxalate decarboxylase
Drug Alias NameTRA-16
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionOxalic acid inhibitors
TargetsOxalic acid
Therapy Area/IndicationsHyperoxaluria, SecondaryHyperoxaluria
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesWuhan Kangfu De Urolithiasis Research Institute Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesWuhan Kangfu De Urolithiasis Research Institute Co Ltd
Inactive CompaniesN/A
Active IndicationsHyperoxaluria, Secondary
Inactive IndicationsHyperoxaluria

Other Information

ATC CodeN/A
Related LinksN/A